[FLASH INFO] ACCORD DE PARTENARIAT

[FLASH INFO] ACCORD DE PARTENARIAT

Oncodesign, Cynbiose, ERBC, Aepodia et PharmaLex a.r.c & Belgium signent un accord de partenariat pour le développement précoce, préclinique et clinique.

Oncodesign, Cynbiose, CERB & Aepodia & PharmaLex a.r.c & Belgium ont le plaisir d'annoncer la signature d'un accord de partenariat visant à fournir à l'industrie biotechnologique et pharmaceutique une offre de services complète allant de l'identification des cibles à la recherche préclinique et aux développements réglementaires jusqu’aux premiers essais chez l'homme. Ce réseau établi de sociétés a vu une opportunité de fournir des services à plus forte valeur ajoutée à des clients du monde entier.

Alors que l'industrie biopharmaceutique s'oriente vers le développement de candidats médicaments plus complexes et d'approches hautement personnalisées, nous sommes convaincus que notre réseau d'organismes de recherche collaboratifs et créatifs offre une solution efficace pour libérer le potentiel d'innovation. La combinaison de nos expertises permettra d'accélérer les projets innovants, de la découverte à la clinique. Nous réunissons des plates-formes technologiques, des compétences et des connaissances, ainsi que la capacité à mettre en place une structure de gouvernance de projet appropriée dans le cadre d'une compréhension globale du processus de développement de médicaments.

Contactez nous pour en savoir plus

La signature de cet accord de partenariat fait suite à la 1ère édition du symposium qui s'est tenu en septembre 2019 à Paris : «Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers».

Le symposium visait à explorer les tendances actuelles en matière de découverte et de développement d'immunothérapies d'un point de vue académique, industriel et réglementaire. Trois leaders d'opinion clés sont montés sur scène pour partager leurs recherches, leurs découvertes et leurs idées. Des tables rondes de grande qualité ont eu lieu dans l'après-midi, dirigées par tous les co-organisateurs. L'accent a été mis sur une compréhension et une collaboration étroite entre tous les partenaires, ce qui a permis d'aboutir à des solutions scientifiques de grande qualité.

Lire le point de vue des 3 KOLs [-Document en anglais]

[Symposium]- MIS À JOUR 14/09/2020 - [EN] Innovative & integrated solution providers in translational research to develop immunotherapies - 30 Septembre - Paris - France

[Symposium] [EN] Innovative & integrated solution providers in translational research to develop immunotherapies - 30 Septembre - Paris - France

The aim of this symposium is to address the current trends in Immunotherapies discovery & development from an academic, industrial and regulatory affairs point of view. Discover how collaborative research organizations can bring their added values within this context, and read the news report to know more about the research, findings & insights of the three key leaders opinion.

News report – Innovative Solution Providers’ symposium focused on immunotherapies

On September 30, 2019, 100 scientific professionals gathered in Paris for the 1st edition of a unique symposium to discuss ‘Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers.

Exploring the current trends in immunotherapies discovery & development from an academic, industrial & regulatory affairs point of view, the event was well received. Three expert speakers took to the stage to share research, findings & insights.

Dr Laurence Laigle, director of translational & clinical research, Center for Therapeutic Innovation, Immuno-Inflammatory Diseases, Servier, shared her views on the 'Clinical Development of Immunotherapies: The Promise of Clinical Translation'. Over the past 60 years, a lot of trials have failed, probably in part because of disease heterogeneity. Implementing a precision medicine approach is vital. It is about making a hypothesis to be tested in different models involving biomarker-led clinical trials; an iterative process that requires access to blood & tissue from large patient cohorts.

Professor Benoit Van Den Eynde, director, Ludwig Institute for Cancer Research, added «Preclinical research in oncology has to change. One of the best ways to improve outcomes is to combine immunotherapies with something else, for example, radiotherapy. Only then will we start to see more improved outcomes for our patients.»

Professor Marc Pallardy, head of the Department of Toxicology, Faculty of Pharmacy, University of Paris-Sud, France, concluded by speaking on ‘Regulatory Aspects for Non-Clinical Development of Immunotherapy Test Items’. He underlined the adverse effects detected in clinics, from which a lot has been learnt about the biology and the mechanism of action of biologics.

In most of these cases, it is important to integrate the known biological activity of the molecule to address the human safety of these molecules (anti-CD3, IL-2, trastuzumab); knowledge of interspecies differences regarding the biology of the target is also essential.

Five high quality roundtables took place in the afternoon, led by Oncodesign and co-organisers ERBC, Cynbiose, Aepodia and PharmaLex. The focus was on tight understanding and collaboration between all partners, resulting in high quality scientific solutions. According to Philippe Genne, CEO of Oncodesign: «This first symposium was a great success. We were able to explore and discuss the current trends in immunotherapies discovery and development from an academic, industrial and regulatory affairs point of view. We believe that innovative clinical programs require a collaborative, creative approach between pharma and biotech companies.»

CONTACT US


[Symposium]- Innovative & integrated solution providers in translational research to develop immunotherapies

The development of immunotherapies faces major challenges such as the inability to predict treatment efficacy and patient response; the need for additional biomarkers; the development of resistance to immunotherapies; the lack of translational tools; the optimization of clinical study designs thanks to precision medicine.

Therefore, expected innovations should include more targeted treatments, the development of personalized biomarker profiles, drug combination therapies to improve efficacy and reduce toxicity.

Open innovation can be tapped and used to open up the necessary and expected innovations thanks to the cross-linking of knowledge and know-how from both Pharma or Biotech industries and external innovation partners.

Within this framework, Oncodesign has built up a network of key partners (Cynbiose, CERB & Aepodia & PharmaLex) convinced that these complex developments require the use of a collaborative and creative research organizations network permitting Pharma or Biotech companies to manage innovative projects from discovery stage to clinical trials. We bring together technological platforms, skills and knowledge, ability to set up an appropriate project governance structure within a comprehensive view of the immunotherapy development process.

[Communiqué de Presse] Oncodesign annonce une augmentation de capital réservée au Comité de Direction de la Société

10/09/2020

TELECHARGER

[Webinaire] [EN] MRI: going beneath the surface in preclinical oncology

 Stream our webinar

Voir la présentation en ligne [Webinaire] [EN] MRI: going beneath the surface in preclinical oncology

Some aggressive tumor types seem to not care where they grow, while the phenotypes other deadly cancers, including their drug sensitivities, can be highly influenced by the correct tumor microenvironment. To study the latter tumor types, the use of OT models to supplement SC modeling is well established in literature and industry practice. However, OT modeling presents several operational challenges, including managing animal health and quantification of tumor size, for the sake of simplicity, we often resort to using regular subcutaneous models for a therapeutic proof of concept.

If MRI enabled tumor growth monitoring in an orthotopic model as simply as in a subcutaneous model, would you change your mind? If we showed you that the efficacy of some compounds is observed only in orthotopic models, would you make the bet to gain time and money and, switch to MRI follow-up?

The goal of this webinar is to highlight our MRI study workflow and show you how we have improved the routine throughput to optimize the homogeneity of randomization and tumor volume monitoring, while increasing the quality of your preclinical data package and limiting the number of animals. Using common models (including MBT-2 bladder, U87 glioma, BT474 breast metastases, liver, prostate and others), we will illustrate Oncodesign deep experience in these advance translational models, and will present the requirements and best practices for these studies.
This standard process will serve the starting point for more advanced MRI studies. Once you’ve got a taste for it, you won’t ever go back to preclinical studies without imaging!

Key learning objectives

  • MRI: a tool for preclinical oncology studies
  • Orthotopic tumor models: how can MRI improve your study
  • Operational efficiency for high-throughput, high group-number studies

Discover our speaker Peggy Provent 

Peggy Provent obtained a PhD in 2006 in Physics from the University of Grenoble, France, where she mainly worked on the development of novel MRI technics to characterize brain tumors in preclinical models.
Peggy joined Oncodesign in 2008 as a study director in the Pharmaco-Imaging Unit. She has been participating in the development of the preclinical imaging platform including Pharm’Image. As a physicist, she supervises all our imaging equipment, data management and image analyses with the goal to always improve the throughput and the quality of our pharmacology studies.

Voir la présentation en ligne

%MCEPASTEBIN%